Kornimate/medical-research-clean huggingface dataset:
effect of core stability exercises on hand functions in children with hemiparesis

Conditions: Cerebral Palsy

Summary: background: impaired upper extremity is the major disability facing the children with hemiplegia as the inability to use hands for reach; grasp and manipulation affect their daily life activities. little attention has been given to gain perspective about abnormal movements that are detectable in hemiplegic cerebral palsy that are related to one's level of core stability and how they affect their hand functions.

background: impaired upper extremity is the major disability facing the children with hemiplegia as the inability to use hands for reach; grasp and manipulation affect their daily life activities. little attention has been given to gain perspective about abnormal movements that are detectable in hemiplegic cerebral palsy that are related to one's level of core stability and how they affect their hand functions. objective: the purpose was to investigate the effectivness of core stability exercises on hand functions in hemiplegic cerebral palsy. methods: thirty hemiparetic cerebral palsied children of both sexes, ranged in age from 6 to 8 years enrolled in this study. they randomly assigned into two groups of equal number. group (a) received the selective physiotherapy exercises and group (b) received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks. time motor performance, gross manual dexterity and skills of the upper extremity were assessed by using jebsen taylor test (jthft), box and block test (bbt) and quality upper extremity skill test (quest) respectively before and after treatment.

Eligibility criteria:
inclusion criteria: * the level of gross motor function ranged from ii to iii, according to gross motor function classification system * all participants are cognitively capable and competent of interpreting and following instructions exclusion criteria: * if they had fixed contractures or deformities of the spine, upper or lower extremities, * visual or respiratory disorders, orthopedic surgery on their involved upper extremity; * dorsal rhizotomy; * botulinum toxin therapy in the upper extremity musculature during the past 6 months * who wished to receive it within the period of study
the use of constant-flow technique for determining the lower inflexion point of pressure-volume curve and intrinsic peep during one-lung ventilation

Conditions: One Lung Ventillation (OLV); Two Lung Ventillation (TLV); Positive End Expiratory Pressure (PEEP); Zero End-expiratory Pressure (ZEEP)

Summary: one method for treating intraoperative hypoxia during one-lung ventilation (olv) is application of peep to the dependent lung. however, only a minority of patients benefit from this maneuver. the effect of applied peep on oxygenation depends on the relation between the total end-expiratory pressure and the lower inflexion point (lip) of pressure-volume curve (1). lip during olv can be determined with super-syringe technique, but is too complicated for routine operating room use. an alternative is the constant-flow method which is easy and widely used in intensive care settings (2). the investigators goal was to confirm that the constant-flow method as applied by an intensive care ventilator works during olv. methods: after irb approval and written, informed consent, data were obtained from 20 patients during olv for thoracic surgery who were ventilated with an avea (viasys healthcare) critical-care ventilator. during two-lung ventilation (tlv) and olv 8 ml•kg-1 tidal volume was used. during olv, ventilation periods of ten minutes, with and without 5 cmh2o peep were alternated. during each period, the investigators recorded arterial blood partial pressures, respiratory and hemodynamic values, intrinsic peep (peepi), and lip. peepi and lip were determined using the automatic mode of the ventilator; specifically, lip was determined with a continuous flow of 3l/minute.


Eligibility criteria:
inclusion criteria: * thoracic surgery lung ventillation
ventriculomegaly and gait disturbance in the senior population in the region of västerbotten

Conditions: Idiopathic Normal Pressure Hydrocephalus (INPH); Brain Diseases; Central Nervous System Diseases; Dementia; Gait Disorders, Neurologic; Hydrocephalus, Normal Pressure

Summary: idiopathic normal pressure hydrocephalus (inph) is a treatable disease of the elderly, typically causing gait impariment, dementia and urinary incontinence. the objective of this study is to make an epidemiological survey of inph in umeå, sweden. subjects with self-perceived gait impairments will be identified through a questionnaire. they will go through clinical examinations and have an mri of the brain. a control population will also be investigated to enable comparisons between the populations. the main hypothesis is that the prevalence of inph in the population is higher than what is previoulsy known.


Eligibility criteria:
inclusion criteria: - living in umeå, sweden. exclusion criteria: * age \ 84 years when the questionnaire was sent out. * death at the time for the clinical evaluation.

Keywords: idiopathic normal pressure hydrocephalus
lurasidone hcl - a long term safety phase 3 study of patients with clinically stable schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: lurasidone hcl is a compound being developed for the treatment of schizophrenia. this clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. the study will also assess the long term effectiveness of lurasidone as compared to an active comparator.


Eligibility criteria:
main inclusion criteria: to be eligible to enter the study, each patient must comply with the following inclusion criteria: * subject is 18 to 75 years on the day of signing the consent form (age parameters may be restricted further per local requirements without protocol amendment). * subject meets diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) criteria for a primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90), catatonic (295.20), or residual (295.60) or schizoaffective disorder (295.70) subtypes. * subject is not pregnant or nursing, and is not planning pregnancy within the projected duration of the study. * subject will comply with the study procedures and outpatient visit requirements in the opinion of the investigator. * subject voluntarily agrees to participate in the study by giving written informed consent. main exclusion criteria: to be excluded from entering this study if they fulfil any of the criteria below: * subject has a chronic organic disease of the central nervous system (other than schizophrenia). * subject has current clinically significant or history of, alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months. * in the opinion of the investigator, the subject has any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study. * subject has participated in a study with an investigational compound or device within 30 days of signing informed consent.

Keywords: lurasidone schizophrenia latuda
safety and tolerability of pro-143 ophthalmic solution in healthy volunteers.

Conditions: Conjunctivitis, Bacterial

Summary: study to evaluate the safety and tolerability of pro-143 solution ophthalmic in healthy volunteers.

a phase i, open label and unicentric clinical trial to evaluate the safety and tolerability of pro-143 ophthalmic solution in healthy volunteers.

Eligibility criteria:
inclusion criteria: * healthy male and female. * age ≥ 18 years old at screening visit. exclusion criteria: * any ocular or systemic condition. * patient with one blind eye. * visual acuity of 20/40 in any eye. * use of ocular or systemics medications. * contraindications or sensitivity to any component of the study treatments. * contact lens users. * ocular surgery within the past 3 months.. * women who were not using an effective means of contraception or who were pregnant or nursing. * participation in any studies of investigational drugs within 90 days previous to the inclusion.

Keywords: pro-143 topical antibiotic ophthalmic antibiotic external bacterial infections
the study of cm326 in adult subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a open-label, multi-center study to evaluate the safety and efficacy of cm326 in atopic adrmatitis subjects.

the study consists of 3 periods, a up-to-4-week screening period, a 52-week treatment period and a 8-week safety follow-up period.

Eligibility criteria:
inclusion criteria: * with confirmed atopic dermatitis (ad) at the screening. * have the ability to understand the nature of the study and voluntarily sign the informed consent. * be able to communicate well with investigators and follow up protocol requirements. * the subjects agreed to use highly effective contraceptive measures during the study. exclusion criteria: * not enough washing-out period for previous therapy. * received allergen specific immunotherapy (desensitization) within 6 months prior to baseline. * major surgery is planned during the study period. * women who are pregnant or breastfeeding, or who plan to become pregnant during the study.
prevention of postoperative acute kidney injury

Conditions: Acute Kidney Injury

Summary: postoperative acute kidney injury (aki) refers to increased mortality and morbidity in patients after non-cardiac surgery. the kidney disease improving global outcomes (kdigo)-guidelines recommend a bundle of procedures to prevent the occurrence of aki: a protocol for the improvement of the hemodynamic situation and a standardized proceeding in hemodynamic monitoring, consequent avoidance of nephrotoxic substances, regular measurement of creatinine and urine output, as well as normoglycemia. the primary goal is to determine if the consequent application of the kdigo-bundle leads to a prevention of the occurrence of aki in patients at risk after non-cardiac surgery.

all patients included in the study will be treated with the kdigo-bundle (hemodynamic stabilization, avoidance of nephrotoxic substances, normoglycemia and measurement of creatinine in serum and urine output). 12 h, 24h as well as on day 2, 3, 5 and 10 after admission on icu the occurence of aki (according to kdigo) will be assessed.

Eligibility criteria:
inclusion criteria: * age \> 65 years * chronic kidney disease * diabetes mellitus, chronic heart, lung or liver disease * hemodynamic instability (intra and/or post-operative) * trauma, burn injury, major surgery, usage of x-ray contrast and sepsis. exclusion criteria: * age \< 18 years * pregnancy * kidney graft recipient * chronic renal disease with or without renal replacement therapy and cardiac surgery.

Keywords: acute kidney injury hemodynamic stabilisation nephrotoxic medication
xylitol disk use in adults with dry mouth

Conditions: Mutans Streptococci; Xerostomia

Summary: the purpose of this study is to demonstrate whether decay causing bacteria are reduced when adhesive xylitol disks are used intraorally three times a day for two weeks in adults with dry mouth.

xylitol,an fda approved sugar substitute, has been shown to reduce tooth decay. patients who experience dry mouth may be more susceptible to dental decay because they lack the protection provided by an adequate flow of saliva. these patients are likely to have high levels of the decay causing bacteria, mutans streptococci. the purpose of this research is to test the ability of a novel xylitol delivery vehicle to reduce mutans streptococci in patients with dry mouth over a two week period. the delivery vehicle is a slowly dissolving xylitol disk (lozenge) that adheres to soft tissues inside the mouth. participants will place disks on both sides of the mouth three times a day.

Eligibility criteria:
inclusion criteria: * adults 21 years old or older * daily use of at least 2 prescription medications known to cause dry mouth * current report of dry mouth exclusion criteria: * antibiotic use in the last month * topical oral antimicrobial (e.g. chlorhexidine rinse) use in the last month * change in medication or dose within the last month * use of mouthwash within the last week * use of lozenges or chewing gum with 500 mg or more of xylitol on a habitual basis * history of gastrointestinal disease

Keywords: xylitol dental caries
visualization of the papilla through use of the nuview device in patients with fap

Conditions: Familial Adenomatous Polyposis

Summary: the goal of this observational study is to test the nuview device in participants with familial adenomatous polyposis (fap). the main question it aims to answer is: * can the papilla be visualized using a forward-facing endoscope outfitted with the nuview device. participants will undergo standard of care esophagogastroduodenoscopy with an additional endoscopic exam using nuview device, for which participant have given prior consent.

the clinical practice at vanderbilt university medical center will first perform the routine upper endoscopic exam with a forward-viewing gastroscope to evaluate the patient's esophagus, stomach, and duodenum. after this has been completed, the forward-viewing endoscope will be removed from the patient and outfitted with the endotheia nuview. the endoscope with nuview will then be inserted transorally down the esophagus, traverse the stomach, and be passed into the duodenum for visualization of the papilla. after the papilla is visualized, the endoscope with nuview will be removed from the patient. as per standard of care, the conventional side-viewing endoscope will then be inserted transorally down the esophagus, traverse the stomach, and be passed into the duodenum for visualization of the papilla. the side-viewing endoscope will then be removed from the patient. the investigators plan to enroll 3 fap patients who are already scheduled to undergo their standard of care endoscopic exam. the primary endpoint of the study is successful visualization of the papilla with the nuview platform.

Eligibility criteria:
inclusion criteria: * male or female, 18 to 70 years of age. * able to provide written informed consent. * have fap exclusion criteria: * females who are pregnant. as part of routine pre-operative care, all females of childbearing potential will undergo either urine or blood pregnancy testing. * cancer positive subjects or any patients currently undergoing any treatment or therapy to treat, cure, or mitigate cancer. * patients who do not meet inclusion criteria * patients who are unable or unwilling to provide informed consent
psychological symptom change in veterans after six sessions of eft (emotional freedom techniques)

Conditions: Stress Disorders, Post-Traumatic

Summary: eft (emotional freedom techniques) has been shown to significantly reduce post-traumatic stress disorder (ptsd) and other psychological symptoms such as anxiety and depression in a variety of clinical trials. this study examines the effect of a six session eft protocol on the symptoms of veterans with clinical scores on the ptsd checklist-military (pcl-m). subjects in the experimental group receive eft coaching supplemental to, and supportive of, the "usual care" treatment provided by their primary care provider. subjects in the wait list control group receive usual care for a month, with pre and posttests, after which they also receive the eft coaching protocol. subjects are followed at three month intervals to determine if gains are maintained, and whether the symptom reductions are similar to those observed in other trials of eft.


Eligibility criteria:
inclusion criteria: * military service * the ability to follow instructions, complete written forms, and provide informed consent. * remaining under the care of a primary care provider such as a va hospital throughout the entire period of the study * between 18 and 90 years old exclusion criteria: * participants with a score of more than 3 on questions 34 and 35 of the symptom assessment-45 questionnaire (sa-45) will receive phone/skype sessions, not office visits

Keywords: veterans, ptsd, eft (emotional freedom techniques), depression, anxiety
ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with and without ribavirin in treatment-naive hcv genotype 1-infected adults

Conditions: Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Summary: this open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for either 4 or 6 weeks in treatment naive adults with chronic hcv-genotype 1 infection without cirrhosis


Eligibility criteria:
inclusion criteria: 1. male or female at least 18 years of age at time of screening 2. chronic hepatitis c virus (hcv) infection prior to study enrollment 3. screening laboratory results from the central clinical laboratory indicating hcv genotype 1 infection only 4. absence of cirrhosis and advanced bridging fibrosis exclusion criteria: 1. positive test result for hepatitis b surface antigen (hbsag) or human immunodeficiency virus (hiv) positive immunoassay 2. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject an unsuitable candidate for this study or treatment with ribavirin (rbv) in the opinion of the investigator 3. any current or past clinical evidence of cirrhosis such as ascites or esophageal varices, or prior biopsy showing cirrhosis or advanced bridging fibrosis, e.g., a metavir score \> 2 or an ishak score \> 3 4. use of medications contraindicated for ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir, or ribavirin (rbv; for those that receive rbv), within 2 weeks or 10 half-lives whichever is longer, prior to study drug administration 5. current enrolment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available anti-hcv agents

Keywords: treatment naive hepatitis c genotype 1
risk factors for mortality for covid-19 admitted to an intensive care unit

Conditions: Covid19; Critically Ill

Summary: studying clinical characterization of critically ill covid-19 patients in a single center studying risk factors for day 28 mortality in covid-19 patients admitted to intensive care unit

an observational study looking into clinical characterization of the novel coronavirus disease 2019 (covid-19) in patients admitted, critically ill, into intensive care unit of hospital queen elizabeth between 1st october 2020 until 31st january 2021. analysis also would be looking into the risk factors into day 28 mortality of these patients

Eligibility criteria:
inclusion criteria: * all patients admitted to the icu in hospital queen elizabeth, kota kinabalu between 1st october 2020 until 31st january 2021 * confirmed covid-19 positive using rt-pcr or rtk-ag either before or during admission in icu exclusion criteria: * patients that were admitted in icu suspected to have covid-19 and died in icu which subsequently to be covid-19 negative

Keywords: covid-19 critically ill mortality day 28
pulmonary rehabilitation innovation and microbiota in exacerbations of copd

Conditions: COPD Exacerbation; COPD

Summary: prime goal is to early detect and treat acute exacerbations of chronic obstructive pulmonary disease (aecopd). this is important since copd accelerates aging and represents major burden worldwide and in portugal, mainly due to its frequent aecopd. pulmonary rehabilitation (pr) is an effective strategy of its management but it is scarce. when aecopd are early detected and treated, it optimizes patients' outcomes and reduces the burden of copd, especially if pr is used. however, up to date, there is no model to predict aecopd for clinical practice. the lung microbiota shows promise to overcome this barrier and inform on copd trajectory and will be investigated. in addition, despite of most aecopd being managed in the community, pr is mainly available in hospitals and less than 1% of patients are having access. thus, community-based pr will be implemented and a clinical decision tool developed for prioritizing who will most benefit from pr, enhancing evidence-based access to pr.

prime aims to address these two gaps, establishing the role of microbiota and clinical data in predicting aecopd and increasing the evidence on pr in aecopd through the translation of pr guidelines to the community. specifically, it aims to: * explore the longitudinal changes in microbiota and clinical data between stable and exacerbations periods; * establish the feasibility and short- and long-term effects of community-based pr for aecopd; * define the characteristics of patients who most benefit from community-based pr. 156 patients with copd will be followed monthly for a year and their lung microbiota and clinical data will be analysed. community-based pr will be delivered to 56 patients. data will be collected before, at 3 weeks, after pr and at 6 months to assess the feasibility and effects of pr. a clinical decision-making tool (cdmt) to prioritise patients with aecopd for pr will be developed. the experienced multidisciplinary team will ensure the following novel results: * a clinical and lung microbiota profile of patients with copd; * a model of aecopd prediction; * recommendations for community-based pr in aecopd; * a cdmt to prioritise patients with aecopd for pr. prime will contribute to optimise outcomes, improve aecopd healthcare services and reduce the burden with copd.

Eligibility criteria:
inclusion criteria: * patients are eligible if adults (≥18anos) and present a diagnose of chronic obstructive pulmonary disease (copd). exclusion criteria: * patients will be excluded if they had an acute cardiovascular event on the previous month or if they have a significant cardiac, immune, musculoskeletal or neurological impairment, or any other that doesn't allow them to perform tests.

Keywords: microbiota pulmonary rehabilitation